Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels

  • Erika Cecon
  • , Daniela Fernandois
  • , Nicolas Renault
  • , Caio Fernando Ferreira Coelho
  • , Jan Wenzel
  • , Corentin Bedart
  • , Charlotte Izabelle
  • , Sarah Gallet
  • , Sophie Le Poder
  • , Bernard Klonjkowski
  • , Markus Schwaninger
  • , Vincent Prevot
  • , Julie Dam
  • , Ralf Jockers
  • Universität Paris V
  • Univ. Lille
  • CHU Lille
  • Par'Immune
  • Universität Aix-Marseille

Abstract

COVID-19 is a complex disease with short- and long-term respiratory, inflammatory and neurological symptoms that are triggered by the infection with SARS-CoV-2. Invasion of the brain by SARS-CoV-2 has been observed in humans and is postulated to be involved in post-COVID state. Brain infection is particularly pronounced in the K18-hACE2 mouse model of COVID-19. Prevention of brain infection in the acute phase of the disease might thus be of therapeutic relevance to prevent long-lasting symptoms of COVID-19. We previously showed that melatonin or two prescribed structural analogs, agomelatine and ramelteon delay the onset of severe clinical symptoms and improve survival of SARS-CoV-2-infected K18-hACE2 mice. Here, we show that treatment of K18-hACE2 mice with melatonin and two melatonin-derived marketed drugs, agomelatine and ramelteon, prevents SARS-CoV-2 entry in the brain, thereby reducing virus-induced damage of small cerebral vessels, immune cell infiltration and brain inflammation. Molecular modeling analyses complemented by experimental studies in cells showed that SARS-CoV-2 entry in endothelial cells is prevented by melatonin binding to an allosteric-binding site on human angiotensin-converting enzyme 2 (ACE2), thus interfering with ACE2 function as an entry receptor for SARS-CoV-2. Our findings open new perspectives for the repurposing of melatonergic drugs and its clinically used analogs in the prevention of brain infection by SARS-CoV-2 and COVID-19-related long-term neurological symptoms.

OriginalspracheEnglisch
Aufsatznummer361
ZeitschriftCellular and Molecular Life Sciences
Jahrgang79
Ausgabenummer7
Seiten (von - bis)361
ISSN1420-682X
DOIs
PublikationsstatusVeröffentlicht - 13.06.2022

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Coronavirus-Bezug

  • Forschung zu SARS-CoV-2 / COVID-19

Fingerprint

Untersuchen Sie die Forschungsthemen von „Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren